FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046125818> ?p ?o ?g. }

• W3046125818 abstract "Background Traumatic hyphema is the entry of blood into the anterior chamber (the space between the cornea and iris) subsequent to a blow or a projectile striking the eye. Hyphema uncommonly causes permanent loss of vision. Associated trauma (e.g. corneal staining, traumatic cataract, angle recession glaucoma, optic atrophy, etc.) may seriously affect vision. Such complications can lead to permanent impairment of vision. People with sickle cell trait/disease may be particularly susceptible to increases of elevated intraocular pressure. If rebleeding occurs, the rates and severity of complications increase. Objectives To assess the effectiveness of various medical interventions in the management of traumatic hyphema. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2018, Issue 6); MEDLINE Ovid; Embase.com; PubMed (1948 to June 2018); the ISRCTN registry; ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). The date of the search was 28 June 2018. Selection criteria Two review authors independently assessed the titles and abstracts of all reports identified by the electronic and manual searches. In this review, we included randomized and quasi‐randomized trials that compared various medical (non‐surgical) interventions versus other medical intervention or control groups for the treatment of traumatic hyphema following closed‐globe trauma. We applied no restrictions regarding age, gender, severity of the closed‐globe trauma, or level of visual acuity at the time of enrollment. Data collection and analysis Two review authors independently extracted the data for the primary outcomes, visual acuity and time to resolution of primary hemorrhage, and secondary outcomes including: secondary hemorrhage and time to rebleed; risk of corneal blood staining, glaucoma or elevated intraocular pressure, optic atrophy, or peripheral anterior synechiae; adverse events; and duration of hospitalization. We entered and analyzed data using Review Manager 5. We performed meta‐analyses using a fixed‐effect model and reported dichotomous outcomes as risk ratios (RR) and continuous outcomes as mean differences (MD). Main results We included 20 randomized and seven quasi‐randomized studies with a total of 2643 participants. Interventions included antifibrinolytic agents (systemic and topical aminocaproic acid, tranexamic acid, and aminomethylbenzoic acid), corticosteroids (systemic and topical), cycloplegics, miotics, aspirin, conjugated estrogens, traditional Chinese medicine, monocular versus bilateral patching, elevation of the head, and bed rest. We found no evidence of an effect on visual acuity for any intervention, whether measured within two weeks (short term) or for longer periods. In a meta‐analysis of two trials, we found no evidence of an effect of aminocaproic acid on long‐term visual acuity (RR 1.03, 95% confidence interval (CI) 0.82 to 1.29) or final visual acuity measured up to three years after the hyphema (RR 1.05, 95% CI 0.93 to 1.18). Eight trials evaluated the effects of various interventions on short‐term visual acuity; none of these interventions was measured in more than one trial. No intervention showed a statistically significant effect (RRs ranged from 0.75 to 1.10). Similarly, visual acuity measured for longer periods in four trials evaluating different interventions was also not statistically significant (RRs ranged from 0.82 to 1.02). The evidence supporting these findings was of low or very low certainty. Systemic aminocaproic acid reduced the rate of recurrent hemorrhage (RR 0.28, 95% CI 0.13 to 0.60) as assessed in six trials with 330 participants. A sensitivity analysis omitting two studies not using an intention‐to‐treat analysis reduced the strength of the evidence (RR 0.43, 95% CI 0.17 to 1.08). We obtained similar results for topical aminocaproic acid (RR 0.48, 95% CI 0.20 to 1.10) in two studies with 121 participants. We assessed the certainty of these findings as low and very low, respectively. Systemic tranexamic acid had a significant effect in reducing the rate of secondary hemorrhage (RR 0.31, 95% CI 0.17 to 0.55) in five trials with 578 participants, as did aminomethylbenzoic acid as reported in one study (RR 0.10, 95% CI 0.02 to 0.41). The evidence to support an associated reduction in the risk of complications from secondary hemorrhage (i.e. corneal blood staining, peripheral anterior synechiae, elevated intraocular pressure, and development of optic atrophy) by antifibrinolytics was limited by the small number of these events. Use of aminocaproic acid was associated with increased nausea, vomiting, and other adverse events compared with placebo. We found no evidence of an effect in the number of adverse events with the use of systemic versus topical aminocaproic acid or with standard versus lower drug dose. The number of days for the primary hyphema to resolve appeared to be longer with the use of systemic aminocaproic acid compared with no use, but this outcome was not altered by any other intervention. The available evidence on usage of systemic or topical corticosteroids, cycloplegics, or aspirin in traumatic hyphema was limited due to the small numbers of participants and events in the trials. We found no evidence of an effect between a single versus binocular patch or ambulation versus complete bed rest on the risk of secondary hemorrhage or time to rebleed. Authors' conclusions We found no evidence of an effect on visual acuity by any of the interventions evaluated in this review. Although evidence was limited, it appears that people with traumatic hyphema who receive aminocaproic acid or tranexamic acid are less likely to experience secondary hemorrhaging. However, hyphema took longer clear in people treated with systemic aminocaproic acid. There is no good evidence to support the use of antifibrinolytic agents in the management of traumatic hyphema other than possibly to reduce the rate of secondary hemorrhage. Similarly, there is no evidence to support the use of corticosteroids, cycloplegics, or non‐drug interventions (such as binocular patching, bed rest, or head elevation) in the management of traumatic hyphema. As these multiple interventions are rarely used in isolation, further research to assess the additive effect of these interventions might be of value." @default.
• W3046125818 created "2020-08-03" @default.
• W3046125818 creator A5003898790 @default.
• W3046125818 creator A5005672858 @default.
• W3046125818 creator A5015045961 @default.
• W3046125818 creator A5043525266 @default.
• W3046125818 creator A5066196510 @default.
• W3046125818 date "2019-01-14" @default.
• W3046125818 modified "2023-09-30" @default.
• W3046125818 title "Medical interventions for traumatic hyphema" @default.
• W3046125818 cites W11484022 @default.
• W3046125818 cites W1430307374 @default.
• W3046125818 cites W1495253423 @default.
• W3046125818 cites W1524008514 @default.
• W3046125818 cites W1545049674 @default.
• W3046125818 cites W186064315 @default.
• W3046125818 cites W1966444998 @default.
• W3046125818 cites W1973954684 @default.
• W3046125818 cites W1978660546 @default.
• W3046125818 cites W1978733924 @default.
• W3046125818 cites W1984162725 @default.
• W3046125818 cites W1990077521 @default.
• W3046125818 cites W1993911607 @default.
• W3046125818 cites W1995945983 @default.
• W3046125818 cites W1998170131 @default.
• W3046125818 cites W1999266569 @default.
• W3046125818 cites W2003468508 @default.
• W3046125818 cites W2004266671 @default.
• W3046125818 cites W2006590365 @default.
• W3046125818 cites W2019311724 @default.
• W3046125818 cites W2024871631 @default.
• W3046125818 cites W2028454209 @default.
• W3046125818 cites W2029133786 @default.
• W3046125818 cites W2033975251 @default.
• W3046125818 cites W2034499121 @default.
• W3046125818 cites W2038511713 @default.
• W3046125818 cites W2039118919 @default.
• W3046125818 cites W2043712734 @default.
• W3046125818 cites W2052921887 @default.
• W3046125818 cites W2055968068 @default.
• W3046125818 cites W2058026018 @default.
• W3046125818 cites W2060359167 @default.
• W3046125818 cites W2065935438 @default.
• W3046125818 cites W2072784997 @default.
• W3046125818 cites W2072988978 @default.
• W3046125818 cites W2077768936 @default.
• W3046125818 cites W2093225995 @default.
• W3046125818 cites W2130718617 @default.
• W3046125818 cites W2147415033 @default.
• W3046125818 cites W2160823853 @default.
• W3046125818 cites W2164042136 @default.
• W3046125818 cites W2244242367 @default.
• W3046125818 cites W2246517044 @default.
• W3046125818 cites W2275884594 @default.
• W3046125818 cites W2338118404 @default.
• W3046125818 cites W2395076513 @default.
• W3046125818 cites W2395178488 @default.
• W3046125818 cites W2395199903 @default.
• W3046125818 cites W2395243046 @default.
• W3046125818 cites W2395633687 @default.
• W3046125818 cites W2397708614 @default.
• W3046125818 cites W2399350462 @default.
• W3046125818 cites W2399519095 @default.
• W3046125818 cites W2403365344 @default.
• W3046125818 cites W2406010714 @default.
• W3046125818 cites W2408273801 @default.
• W3046125818 cites W2409310266 @default.
• W3046125818 cites W2409500090 @default.
• W3046125818 cites W2409501082 @default.
• W3046125818 cites W2410049350 @default.
• W3046125818 cites W2410217572 @default.
• W3046125818 cites W2410605680 @default.
• W3046125818 cites W2411030228 @default.
• W3046125818 cites W2411245702 @default.
• W3046125818 cites W2411818338 @default.
• W3046125818 cites W2413576938 @default.
• W3046125818 cites W2415119417 @default.
• W3046125818 cites W2415739301 @default.
• W3046125818 cites W2416077023 @default.
• W3046125818 cites W2416157443 @default.
• W3046125818 cites W2417516652 @default.
• W3046125818 cites W2417681573 @default.
• W3046125818 cites W2418587101 @default.
• W3046125818 cites W2419117820 @default.
• W3046125818 cites W2419519764 @default.
• W3046125818 cites W2422395613 @default.
• W3046125818 cites W2423511789 @default.
• W3046125818 cites W2426911405 @default.
• W3046125818 cites W2432687919 @default.
• W3046125818 cites W2460537962 @default.
• W3046125818 cites W2462045945 @default.
• W3046125818 cites W2463264506 @default.
• W3046125818 cites W2465602901 @default.
• W3046125818 cites W2466278711 @default.
• W3046125818 cites W2469478540 @default.
• W3046125818 cites W2474090591 @default.
• W3046125818 cites W2477026162 @default.
• W3046125818 cites W2991728418 @default.
• W3046125818 cites W2993590581 @default.
• W3046125818 cites W3147437720 @default.

• next